Growth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinase.

Abstract

Adenosine monophosphate (AMP)-activated protein kinase is a recently identified downstream target of calcium/calmodulin-dependent protein kinase kinase-beta, and is involved in the regulation of cell metabolism and cell proliferation. STO-609 is a selective antagonist of calcium/calmodulin-dependent protein kinase kinase-beta. In the present study, we found that STO-609 suppressed AMP-activated protein kinase activity, reduced expression of Akt and ERK, and increased cell apoptosis in SNU-1 and N87 cells but not normal gastric epithelial cells (CCL-241). Interestingly, we found such effects of STO-609 on gastric cancer cells were not affected after the knock-down of CaMKK-β and AMPK. In conclusion, STO-609 is an effective cytotoxic agent for gastric adenocarcinoma in vivo.

• Authors: Zhiming Ma, Dacheng Wen, Xudong Wang, Longfei Yang, Tianzhou Liu, Jingjing Liu, Jiaming Zhu, Xuedong Fang
• Journal: American journal of translational research (Am J Transl Res) Vol. 8 Issue 2 Pg. 1164-71 ( 2016) ISSN: 1943-8141 [Print] United States
• PMID: 27158402 (Publication Type: Journal Article)